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Abstract
Primary sarcopenia is considered to be age-related when no other cause is evident, other 
than aging itself. Secondary sarcopenia should be considered when one or more other 
causes are evident, such as multiple chronic conditions. Previous studies have reported 
that low muscle strength and impaired physical performance can be found in chronic 
diseases, including metabolic disease (diabetes, hypertension, and obesity), arthritis, 
osteoporosis, cancer, chronic kidney disease, chronic obstructive pulmonary disease, 
neuromuscular disease, and chronic infection. The development of preventive and thera-
peutic strategies against secondary sarcopenia and wasting disorders in general is an 
epidemiological need. The planning of a complex rehabilitation program in sarcopenia 
associated to chronic conditions, in the context of a comprehensive treatment, is made 
up of a nutritional support, exercise, correction of lifestyles, and the use of advanced 
physical energies. Therefore, for the purposes of the optimal management, it is essential 
to identify the pathogenesis and clinical characteristics that can affect the different reha-
bilitative treatment.
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1. Introduction
Many definitions available on sarcopenia agree on to define it as paraphysiological phenom-
enon, characterized by loss of muscle mass that occurs with aging.
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Some authors emphasize the histopathology defining sarcopenia as an increase of the adipose 
and connective component within the muscle itself, whereas others focus on the reduction of 
muscle strength and physical function [1, 2].
Cachexia is a composite word from the Greek words “kakos” (bad) and “hexis” (condition) and 
refers to the prognosis and functionality of patients suffering from cachexia. The characteristic 
of this complex metabolic disturbance is weight loss due to an underlying cause disease, such 
as heart failure, chronic pulmonary diseases, or cancer. According to the definition given by 
Cruz-Jentoft et al. in 2010, cachexia is found in patients with unintentional weight loss of 5% 
in the past year, a body mass index (BMI) lower than 20, decreased muscle mass as shown 
with bioimpedance analysis (BIA) or dual-energy X-ray absorptiometry (DEXA), low muscle 
strength, low serum albumin levels, anemia, and elevated biomarkers of inflammation [2].
Weight loss becomes a clinical sign of any progressive acute or chronic disease state. In its 
extreme form, it involves a significant lean body mass (including skeletal muscle) and fat 
loss. Skeletal muscle provides a fundamental basis for human function, enabling locomotion, 
and respiration. Muscle wasting is related to a poor quality of life and increased morbidity/
mortality [3].
2. Sarcopenia in chronic illness
Sarcopenia can be defined as primary sarcopenia when due to the aging process and second-
ary when due to comorbidities, malnutrition, or immobility (Figure 1).
Figure 1. Classification of sarcopenia.
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• Comorbidities that induce sarcopenia are organ failure (e.g. heart, kidneys, lungs, brain 
and liver), inflammatory diseases, cancer, and endocrine diseases.
• Malnutrition due to gastrointestinal disorders, anorexia in cases of polypharmacy, and in-
adequate intake due to psychosocial disorders lead to secondary sarcopenia.
• Inactivity as a result postoperative deconditioning or prolonged rehabilitation is the reason 
for activity-related secondary sarcopenia [4].
It has been known for millennia that muscle and fat wasting leads to poor outcomes, including 
deaths in chronic disease states. It is usually accompanied by physical inactivity, decreased 
mobility, slow gait, and poor physical endurance, which are also common features of the 
frailty syndrome. Although the specific contribution of each of these factors is unknown, 
there are more and more convincing evidence of chronic low-grade inflammation prominent 
role in the development of sarcopenia. According to recent studies, chronic inflammation is 
associated with many degenerative diseases [5]. Systemic inflammation is thus dependent 
on many factors that include diseases such as obesity, type 2 diabetes, dementia [5, 6], heart 
failure, and rheumatic diseases [7, 8], which can then be the result of this inflammatory 
condition and/or themselves can be the cause of the increase of inflammation. The impact of 
inflammation on the development of sarcopenia is supported by many studies. Animal stud-
ies show that low-grade inflammation reduction following the administration of ibuprofen 
in rats have determined a significant decrease in the loss of muscle mass [9]. Other stud-
ies, always conducted on animals, have shown that administration of interleukin-6 (IL-6) or 
tumor necrosis factor alpha (TNF-α) increases the skeletal muscle degradation, decreases 
protein synthesis, and reduces plasma concentrations of insulin-like growth factor (IGF) 
[10]. However, considering the studies of healthy elderly people living in the community, it 
was confirmed that one pro-inflammatory state produces, in the long-term, negative effects 
on sarcopenia. In the study “Longitudinal Aging Study Amsterdam,” high levels of IL-6 
and C-reactive protein (CRP) were associated with a double or triple risk of losing more 
than 40% to the hand grip (strength of the handshake) over 3 years. TNF-α, IL-1a, IL-6, 
IL-18, C-reactive protein (CRP) and fibrinogen are among the cytokines and acute phase pro-
teins, that result to be more elevated in pro-inflammatory state [11]. Moreover, high levels 
of muscle catabolic biomarkers, which include IL-6, are important predictors of the decline 
in muscle strength [12]. Other authors report that IL-6 is a multifunctional cytokine because 
it has both pro and anti-inflammatory effects by determining muscular growth or atrophy, 
and according to different conditions, its effect is anabolic or catabolic. Several different 
pathophysiological processes induce sarcopenia following distinct pathways: neurologi-
cal diseases produce sarcopenia by loss of motor neurons. Malabsorption leads to protein 
deficits and muscle catabolism. Disuse of muscles due to physical inactivity is followed by 
muscle degeneration. Hormonal disturbances of the thyroid, hypercortisolism, and insu-
lin resistance lead to sarcopenia resulting from protein deficiency [13, 14]. These processes 
are found in combination or alone in many acute and chronic diseases above all in elderly 
patients, for example heart failure, chronic obstructive pulmonary disease (COPD), diabetes, 
neurological diseases, musculoskeletal diseases, as well as post-traumatic or postoperative 
conditions [15].
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2.1. Sarcopenia: obesity and diabetes
Although the mechanism by which the potential TNF-α and IL-6 increase and the relation-
ship with sarcopenia is not yet well defined, they may be related to the increase of the intra-
muscular adipose tissue. Under the pro-inflammatory stimulus, the intramuscular contents 
and intra-myocellular fat deposits increase creating a vicious circle where adipocytes, which 
secrete IL-6 and TNF-α as well as adipocines such as leptin and adiponectin, further promote 
inflammation [16].
More recently, Newman et al. have shown that it is important to consider in sarcopenia the 
percentage of fat mass. These authors have shown that people with higher body weight is 
not classified as suffering from sarcopenia, though their lean mass is sufficient compared to 
the total body weight [17]. Both sarcopenia and obesity represent, as the individual factors, a 
risk for adverse events, it has been shown that if present in combination, act synergistically 
increasing the earlier onset of disability [18]. For example, Rolland et al. found in a cohort 
study of women with sarcopenia, decreased physical performance (climbing stairs) compared 
to a group of healthy same aged, the worse performance was related to sarcopenia associated 
with obesity [19].
2.2. Chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) is a common cause of morbidity and mor-
tality worldwide. The burden of disease is induced to a great extent by extrapulmonary 
symptoms, such as osteoporosis, heart failure, and sarcopenia. Using only BMI as a predic-
tor of muscle mass or sarcopenia is misleading in these patients because the combination of 
abdominal obesity and sarcopenia is often present [20]. Sarcopenia affects 15% of patients 
with chronic obstructive pulmonary disease (COPD) stable and compromises the indepen-
dence and the functional state of the musculoskeletal system. This loss of muscle mass does 
not seem to affect the outcome of pulmonary rehabilitation, which can lead to remission of the 
syndrome in selected patients. Pulmonary rehabilitation can improve symptoms and quality 
of life of patients with respiratory disease. It releases dyspnea and fatigue, as well as increas-
ing exercise tolerance, emotional function so in indirect way it decreases frailty such as weak-
ness, inactivity and fatigue, and then sarcopenia [21, 22].
It has been reported that patients with COPD and sarcopenia have nearly overlapping results 
after pulmonary rehabilitation compared to patients with COPD without sarcopenia, in terms 
of upper and lower limb strength, exercise capacity and health status [23].
Another important data are the absence of statistical differences about the body composition, 
functional performance, or health status between patients with and patients without sarcope-
nia undergone to pulmonary rehabilitation [24].
Musculoskeletal dysfunction is a recognized manifestation of COPD whose characteris-
tics include the weakness of the quadriceps, the atrophy, and the change of type II fibers, all 
associated with a poor prognosis independent from lung function [25]. COPD determines an 
imbalance favoring protein breakdown over synthesis, apoptosis, sarcomere and sarcolemma 
Frailty and Sarcopenia - Onset, Development and Clinical Challenges164
damage, reduced myosin heavy chain-I isoform type I [slow twitch/endurance] muscle fibers, 
and a decreased density of capillaries and mitochondria [26–28]. This chronic disease is related 
to abnormalities of oxidative enzymes, mitochondrial activity, and expression of myogenin and 
m-cadherin—key molecules required for muscle growth and repair [29]. In chronic conditions, 
the poor peripheral oxygenation linked to abnormalities of gas exchange typical of COPD and 
anemia, as well as increased oxidation processes [30–32] associated with hypercapnia, create an 
acidosis condition that alters muscle proteases [33, 34], increasing catabolic activity in the mus-
cle [35]. In addition, the effect of tobacco is associated with the [36] myopathy induced by cor-
ticosteroid use (especially systemic steroids) [37, 38], malnutrition that has a negative balance 
of energy [39], and reduction of physical activity leading sarcopenia [40]. The other mechanism 
involved in the genesis of sarcopenia is a sedentary lifestyle due not only to previous habits 
but also to reduced exercise tolerance. This was highlighted by disproportionate impairment of 
lower limb musculature in comparison to the upper limbs (that are subjected to a lesser degree 
of physical inactivity than the legs) [41] and by similarity in the structural changes seen in the 
sarcopenia of COPD and atrophy due to muscle disuse [42]. Furthermore, recovery of strength 
is possible with muscle training and conditioning [43, 44], and the apparent lack of correlation 
between the severity of airflow limitation and extent of muscle dysfunction [45]. Rehabilitation 
would therefore be expected to improve frailty and sarcopenia, but there are little published 
data on this as an intervention.
2.3. Sarcopenia: chronic renal failure
Patients with end-stage renal disease (ESRD) and chronic renal failure (CRF) receiving dialysis 
can have altered nutritional status and body composition due to dietary restrictions, level of 
physical activity, co-morbidities, metabolic alterations, and inflammation. Fatigue and immo-
bility due to low muscle function are frequent symptoms reported by patients with chronic 
kidney disease. Sarcopenia is found in all stages of the disease and more distinctly in patients 
with high grades of renal function impairment. Pereira et al. found a significantly higher 
association of sarcopenia, diagnosed by BPA and hand grip strength measurements and mor-
tality [46]. The degradation of proteins is an important energy production mechanism since 
the amino acids are rapidly converted to glucose. In conditions of catabolism generates an 
imbalance in favor of the degradation compared to the synthesis of proteins and, not existing 
a storage of the same, the muscle proteins are degraded and, if not additional sufficiently, 
develop muscle atrophy that determines a condition of sarcopenia [47, 48].
Many diseases promote protein catabolism, including the IRC; in particular, it was noted that 
during and after the hemodialysis session protein degradation is significantly accelerated. 
Several studies have shown that the ubiquitin-proteasome system (UPS) is the major pro-
teolytic system in renal patients (Figure 2); despite prove even other hyperactive pathways 
(lysosomal cathepsin and calpain-gated calcium), caspase is a protease involved in cell apop-
tosis process that accelerates the degradation of the muscle through the reduction of complex 
protein structures in simple proteins, useful substrates for the UPS [49].
Several evidences have shown that patients with CRF, insulin resistance, inflammation, 
metabolic acidosis, and excess of angiotensin II determine high levels of caspase 3 and 
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a significant increase of catabolic processes. These conditions promote the degradation 
of muscle protein, itself CRF can induce and enhance insulin resistance, encouraging 
the development of sarcopenia [50–52]. Another consequence of CRF, even more, of the 
hemodialysis treatment, is the presence of a chronic inflammatory state that, through 
different modulators, including TNF-alpha, suppresses the action of insulin, increases 
blood cortisol levels, and activates caspase-3. Glucocorticoids enhance degradation of 
muscle proteins by upregulation of UPS system. Metabolic acidosis, that is very com-
mon, especially in the case of dialysis treatment, determines sarcopenia through mul-
tiple mechanisms: induces a negative nitrogen balance and protein synthesis, promotes 
protein degradation by the UPS system and caspase 3 and alteration of pathway PI3K/
Akt, which is a critical transduction signal in cell proliferation and cell cycle progression, 
apoptosis, and cellular metabolism. It reduces blood levels of IGF-1 and increases those 
of glucocorticoids. It is probably the main cause of the high prevalence of sarcopenia CFR 
[53]. The dialysis treatment, by itself, may determine, during each session, a damage to 
the protein metabolism, with the loss of amino acids and proteins in the dialysate, which 
reduces the availability of nutrients for muscle synthesis [54]. Many studies, in fact, show 
that the dialysis catabolic effects induce negative impact on the homeostasis of skeletal 
muscle protein with reduction of their synthesis and increase of their degradation [55]. 
Other authors noted that the increased protein lysis persists up to 2 hours after the end of 
hemodialysis session [56].
The mechanisms underlying this alteration of protein turnover were due not only to the 
reduction of circulating levels of amino acids and proteins but also to alterations of the factor 
and EIF2B (eukaryotic translation initiation factor 2 subunit B), which acts in the early steps 
of protein synthesis and activation of the inflammatory cascade [57].
Figure 2. The proteins responsible for muscle degradation are first of all ubiquitin: the enzyme activates the ubiquitin E1, 
activating a cascade of ATP-dependent events. The ubiquitin chain is recognized by the proteasome 19S, which catalyzes 
entrance of the protein substrate in the proteasome core 20S, which is cleaved to peptides of the 26S proteasome. The 
peptides are degraded into amino acids to build cellular proteins or are released from the cells. From: Workeneh BT, 
Mitch WE. Review of muscle wasting associated with chronic kidney disease. The American Journal of Clinical Nutrition 
2010;91(suppl):1128S-1132S.
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2.4. Sarcopenia: chronic heart failure (CHF)
Heart dysfunction is a major factor limiting physical performance and skeletal muscle abnor-
malities, which often accompany CHF, may also contribute to fatigue and dyspnea (Figure 3).
Heart dysfunction is associated by metabolic changes that implicate inflammatory and endo-
crine disorders that determine muscle atrophy and weakness [58].
Cardiac myopathy is defined as muscle fiber atrophy, decreased capillary density, and 
a low number of type I fibers (fast) compared to type 2, with alteration of the normal 
ratio between type 1 fibers and type 2 fibers, changes that are responsible for intolerance 
to physical exercise [59]. Mechanism involved is the ubiquitin-mediated proteolysis and 
anorexia that exacerbate the weight loss process.
The UPS involves a multi-subunit protease that specifically degrades ubiquitin-conjugated 
proteins through the action of three enzymes, the ubiquitin-activating enzyme, the ubiquitin-
conjugating enzyme, and ubiquitin ligases (atrogin-1 and MuRF-1). A higher frequency of 
myonuclear apoptosis has also been found in the muscle of patients with CHF relative to age-
matched healthy controls [60].
In fact, patients develop anorexia that is secondary to intestinal edema with symptoms like 
dysgeusia, nausea, and gastroenteropathy and it is also mediated by several drugs such as 
digoxin, angiotensin-converting enzyme (ACE) inhibitors, β-blockers, and diuretics that favor 
a loss of nutrients. So, an insufficient intake or absorption of primary nutritional elements, or 
their loss, determines a malnutrition condition and muscle depletion.
Figure 3. Pathophysiology of secondary sarcopenia.
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Furthermore, elevation of angiotensin II levels aggravates these mechanisms. High levels 
of angiotensin II increase cytokines, such as TNF-alpha, interleukin 6, and glucocorticoids, 
which induce muscle protein degradation. TNF-α and its soluble receptors have been associ-
ated with declines in muscle mass and strength [61]. Another pathophysiological process is 
related to the decrease of expression of growth hormone (GH) and IGF-1 (anabolic hormones) 
in muscle, possibly contributing to muscle mass loss [62].
2.5. Sarcopenia: cancer
Within neoplastic sarcopenia definition (often described as cachexia), are included both 
the real cases of primary cachexia and the cases of nutritional deterioration secondary to 
obstruction of the digestive tract, chemo-radiotherapy toxicity, and post-surgical intestinal 
malabsorption syndromes (secondary cachexia). Cachexia is, regardless of the histology and 
location of the primary tumor, the most common paraneoplastic syndrome in patients with 
advanced cancer. Over 70% of cancer patients, especially in advanced stages, develop signs 
and symptoms of cachexia, and about 20% die because of its consequences [63].
Cachexia is characterized by alterations of all metabolic systems, production of circulating 
factors in part produced by the tumor, in part by the host cells, mainly macrophages, in 
response to the tumor, and reduced caloric intake.
Some of these alterations appear early in the natural history of neoplastic disease:
a. Glucose metabolism: Increased gluconeogenesis from lactate, amino acids, and free fatty 
acids with loss of protein and lipid reserves.
b. Protein metabolism: Increased turnover with decreased muscle and hepatic protein 
synthesis, increased hepatic synthesis of acute phase proteins, increased serum levels of 
proteolysis-inducing factor (PIF), and increased protein degradation from muscle tissue. 
The activation of muscle proteolytic systems, such as that of the ubiquitin-proteasome, is 
present even before there has been weight loss, suggesting that biomolecular alterations 
responsible for muscular loss are highlighted early in the natural history of neoplastic dis-
ease. Other proteolytic mechanisms provide the activation of calcium-dependent systems, 
such as that of calpain (regulated by a kinase ATP-dependent and an inhibitor, calpastatin).
c. Lipid metabolism: Increased beta-oxidation of fatty acids and the turnover of free fatty 
acids, increased serum lipoprotein, triglycerides, and production of lipid mobilizing factor 
(LMF), which induces lipolysis [64].
Some systemic effects of cancer cachexia, such as anorexia, “fatigue,” and increased resting 
energy expenditure, are the result of circulating factors’ action in part produced by the tumor 
and in part by the host cells, mainly macrophages, in response to the tumor. Among them, a cen-
tral role is given by the pro-inflammatory cytokines (IL-1, IL-6, TNF-α, IFN-γ), which trigger the 
acute phase response with reduced synthesis of proteins (albumin, prealbumin, and transfer-
rin) [65]. Cytokines such as interleukin-1 (IL-1) and tumor necrosis factor-α (TNF-α) have been 
suggested as involved in cancer-related anorexia, possibly by increasing the levels of corticotro-
pin-releasing hormone (CRH), a central nervous system neurotransmitter that suppresses food 
intake, and the firing of glucose-sensitive neurons, which would also decrease food intake [66].
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2.6. Secondary sarcopenia: assessment
The variability of weight, even when expressed as body mass index (BMI), is very wide in 
patients with chronic conditions. There is a correlation between the amount of weight loss 
and survival. The weight loss cannot be explained only by the decreased supply of food. In 
fact, it may be related to the size of the increase in basal metabolic rate (resting energy con-
sumption). It is important at the same time in particular for patients suffering from metabolic 
syndrome and respiratory problems to assess the degree of overweight and obesity.
Therefore, it is necessary to investigate:
• Weight and height (BMI body mass index), and weight loss percentage in the previous 
period (2 weeks, 1 month, or 6 months).
• Assessment of the quantity and quality of food intake (presence or not of dysphagia). The 
term sarcopenic dysphagia means a condition characterized by the presence of dysphagia 
due to sarcopenia of swallowing muscles associated with secondary sarcopenia. Unlike in 
the elderly dysphagia in stroke outcome, the sarcopenic dysphagia is rarely acknowledged, 
probably due to the fact that the definition and diagnostic criteria of this condition have 
not yet been clearly established. According to Butler et al., muscle strength, measured with 
handgrip, correlates directly with the isometric strength of posterior tongue. This obser-
vation indicates that the muscle strength of tongue can be reduced with the generalized 
deficit in skeletal muscle force, like in sarcopenia [67].
The 10-item Eating Assessment Tool (EAT-10) and a water test (e.g. Toronto Bedside 
Swallowing Screening Test) or different viscosities (e.g. Volume-Viscosity Swallowing Test) 
combined with pulse oximetry are useful for dysphagia screening, and if it is confirmed, it 
requires further secondary clinical evaluations (speech therapist) and possibly instrumental 
study (Videofluoroscopic Swallowing Study) [68].
The Mini Nutritional Assessment (MNA) [68] is a multidimensional assessment tool, which is 
easy to complete and allow an easy and feasible large-scale use. The MNA includes 18 items 
divided into three main sectors (anthropometry and variations in weight, measuring quanti-
tative and qualitative food intake, and disability status and cognitive status); the maximum 
score is 30. A score below 17 is indicative of malnutrition, a score between 17 and 23.5 is indic-
ative of risk of malnutrition, and a score greater than 24 indicates a normal nutritional status.
The questionnaire allows to classify the nutritional state in an univoque way and has high 
interpersonal reliability and clearly defined thresholds. It has been validated in several eth-
nicities and ethnic-specific anthropometric cut-off has been set up [69].
The MNA is also a nutrition guide. Timely intervention blocks the weight loss in people who are 
at risk of malnutrition or undernourished. It takes in regard anthropometric, global, dietary, and 
subjective assessment, and it gives to this tool high sensitivity (96%) and specificity (98%) [70].
The scale allows to global assessment of patient as the prevalence of malnutrition increases 
significantly among hospitalized and institutionalized patients and those with cognitive 
impairment. The connection is simple enough to guess, the inability to feed on their own, the 
choice of foods, and the long-lasting immobility.
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Perhaps less intuitive, chronic protein energy malnutrition affects the ongoing development 
of higher cognitive processes rather than simply showing a generalized cognitive and motor 
impairment.
Deficits of cognitive, emotional, and behavioral functioning are linked to structural abnor-
malities of different regions of the brain. Brain structures and brain circuits calculate different 
components of cognitive processes. Malnutrition has long-lasting effects in the processes of 
cognition and behavior [71].
According to the consensus conference of EWGSOP of 2009, the main parameters to be evalu-
ated in the course of sarcopenia relate to muscle mass, muscle strength, and physical perfor-
mance of the subject. Based on these three parameters, sarcopenia can be classified into three 
stages: pre-sarcopenia, sarcopenia, and its severe form [72].
Muscle mass can be assessed by magnetic resonance imaging (MRI) and computed tomogra-
phy (CT); their use is limited in primary care settings by difficulties in access, costs, the lack of 
portable equipment, and the requirement of highly specialized personnel [73].
Dual-energy X-ray absorptiometry (DXA) is used to assess body composition and provides 
reproducible estimates of appendicular skeletal lean mass but it is known that the accuracy of 
DXA for assessing muscle mass in people of different ages and different pathological condi-
tions may vary [74]. Bio-electrical impedance analysis (BIA) estimates the volume of fat and 
lean body mass based on the relationship between the volume of a conductor and its electrical 
resistance. It is not expensive, it can be used easily in clinical practice, both on ambulatory 
subjects and on hospitalized patients [75, 76]. A still not widely used method, but of extreme 
interest for the estimation muscular mass, it is represented by the ultrasounds.
Ultrasound allows to explore parenchymas and soft tissue of the human body, responding 
to all the ideal requirements of a diagnostic method: the almost absolute harmlessness, prac-
ticity, rapidity of implementation, and cost contents. According to Fanelli and Kuczmarski, 
ultrasound application represents a prediction system of body fat that is valid at least as far as 
plicometry [77], but there are still many limitations related to the application of the method: 
there is no conventional choice of best frequency to apply, body position, and probe pressure 
on the surface to be evaluated (Table 1).
This method, by measuring thickness of the muscular layers, visceral and subcutaneous fat, 
was useful in evaluating the regional body composition and where the plicometry is limited 
[78]. In 2012, Leahy et al. [79] took ultrasound and DXA measurements with good predic-
tive accuracy. In addition, others have used ultrasound to predict the body density of lean 
men [77], lean women [80], obese adult, Japanese men and women [81], sumo wrestlers [82], 
the body fat percentage of physically active British and Chinese men [83], and the fat mass 
of pre-pubertal Japanese children. A new technology, a small, portable, hand-held 2.5 MHz 
A-mode ultrasound transducer designed specifically for the purpose of body composition 
assessment; it is connected to a laptop computer using a USB cable, the software assumes the 
acoustic reflections of the fat-muscle and muscle bone interfaces (Body View, IntelaMetrix, 
Inc., Livermore, CA) [84].
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Studies reported qualitative changes in muscle related to sarcopenia (e.g. atrophy of type II 
muscle fibers, increase of intramuscular fat, increase of extracellular water relative to muscle 
volume) and that these abnormalities can be linked to differences in echo intensity obtained 
from ultrasonography images.
Enhanced echo intensity (EI) represents changes caused by increase of intramuscular fat and 
fibrous tissue: an increase of echogenicity indicates greater fibrous tissue and fat between 
muscular fibers (Figure 4) [85]. The simplicity of execution, the low cost, and wide availability 
make them ideal in the evaluation also for bedridden patients.
Muscle strength was assessed by functional tests: handgrip strength, the walking speed, flex-
ion/extension of the thigh muscles, and forced expiratory flow. Handgrip strength appears to 
be the most widely used method for the measurement of muscle strength. Isometric handgrip 
strength shows a good correlation with leg strength and also with lower extremity power, 
knee extension torque, and calf cross-sectional muscle area [86, 87]. Standardized conditions 
for the test [88] include seating the subject in a standard chair with their forearms resting flat 
on the armchairs. Six measures should be taken, three with each arm. Ideally, the patients 
should be encouraged to squeeze as hard and as tightly as possible for 3–5 seconds for each 
of the six trials; usually, the highest reading of the six measurements is reported as the final 
result [89].
The most widely used tool in clinical practice for the assessment of physical performance is 
measured by gait speed alone or as part of a test battery such as short physical performance 
battery (SPPB). The SPPB is a test scored to a maximum of 12 points comprising an assessment 
of gait speed (over 3–4 m), a balance test, and a repeated chair stand test. These tests focus on 
lower extremity function, as the latter has been shown to correlate with mobility, disability, 
and patient outcomes, including hospitalization, institutionalization, and mortality. The SPPB 
takes about 10 min to complete. Participants presenting a score ≤8 points have been described 
as having a poor physical performance [90]. Other standalone tests can be performed to assess 
Advantages Limitations
Lower cost than laboratory methods Higher cost than field methods
High accuracy and precision in the hands of an 
experienced technician
Requires experienced technician, considerable skill is 
necessary
Capable of regional and segmental measurements Measurement procedures and techniques are not yet 
standardized
Minimal tissue compression Inherent artifacts (fascia etc.)
Noninvasive and no ionizing radiation
Applicable for testing in the field
Can measure other tissue thicknesses (muscle and bone)
Short testing time, rapid procedure
Table 1. Advantages and limitations of ultrasound application.
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physical performance. In the Timed Up and Go (TUG) test, individuals are asked to rise from 
a standard armchair, walk to a marker 3 m away, turn, walk back, and sit down again. The 
6-min walk distance or 400 m walk time can be used to measure aerobic capacity. The stair 
climb power test also shows good correlation with other measures of leg power and physical 
performance but is mostly restricted to use in research settings [91].
They have been proposed numerous biomarkers to evaluate the catabolic/anabolic balance 
of skeletal muscle: inflammation biomarkers, such as C-reactive protein, interleukin-6, and 
tumor necrosis factor-α, and other clinical parameters that express the general state of health 
like hemoglobin, serum albumin, and urinary creatinine. In the overall evaluation, it is impor-
tant to measure, also, hormones: dehydroepiandrosterone sulfate, testosterone, insulin-like 
growth factor-1, and vitamin D, products of oxidative damage like advanced glycation end-
products, protein carbonyls, and oxidized low-density lipoproteins, or antioxidants and 
finally α-tocopherol [92].
3. Rehabilitative approach
3.1. Nutritional-supplementary-integrative—intervention
Malnutrition and peripheral insulin resistance, which increases glucose levels in peripheral 
blood, are frequent alterations in pathologies that may cause sarcopenia.
Figure 4. Echo intensity of the rectus femoris muscle. Left: High echo intensity; Right: low echo intensity. EI, echo 
intensity; FT, subcutaneous fat thickness; MT, muscle thickness; RF, rectus femoris muscle; VI, vastus intermedius 
muscle. From Watanabe et al. [85].
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The feeding of patient suffering from sarcopenia is essential, mostly the intake of essential 
amino acids. It should be reminded the importance of 3 protein meals intake and/or supple-
mentation, better if it is given immediately after exercise. The reduced response to the pro-
tein synthesis after ingestion of small amounts of essential amino acids can be increased by 
the ingestion of a mixture with a greater amount of leucine (essential branched-chain amino 
acid) or a supplementation with hydroxy-methyl butyrate (HMB), a metabolite of leucine; 
it promotes protein synthesis by preventing protein breakdown. Hormone replacement 
therapy, if there are no contraindications can be used. According to the recommendations of 
the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and 
Musculoskeletal Diseases (ESCEO), it must be associated to physical exercise, a high protein 
diet (1–1.2 g/kg per day with at least 20–25 g of high quality protein, such as those derived 
from milk) [93]. Rizzoli et al. reported that the recommendations for optimal dietary pro-
tein intake are daily 1.0–1.2 g/kg (body weight) with an optimal repartition over each daily 
meal to prevent sarcopenia [94]. Paddon-Jones et al. proposed a dietary plan that includes 
25–30 g of high quality protein per meal as dietary protein recommendations for the preven-
tion of sarcopenia [95]. A protein-enriched diet equivalent to 1.3 g/kg/day achieved through 
lean red meat is safe and effective for enhancing the effects of progressive resistance training. 
Carnitine plays a decisive role in the metabolism of long-chain free fatty acids, thus affecting 
lipid metabolism and energy reserves within the cells. Carnitine is a necessary cofactor for the 
transport of long-chain fatty acids within the mitochondrial matrix, where they are subjected 
to oxidation for the production of cellular energy. A clinical study has shown that administra-
tion of 6 g/day of L-carnitine for the duration of 30 days was able to significantly improve the 
symptom “fatigue,” appetite, and lean body mass of patients. Therefore, the administration 
of L-carnitine should be recommended in cachectic patients at a dose of 4–6 g/day orally for 
a period of time of 3-4 months being usually well tolerated by the patient. Occasional side 
effects of L-carnitine include epigastralgia and, more rarely, diarrhea [96].
In addition to the now well-known beneficial effects on bone, the vitamin D has positive 
extraskeletal effects; it acts on the muscle directly (receptor have been identified in skeletal 
muscle) and indirectly, through increasing of calcium that is essential for muscle contraction; 
and finally, it promotes the synthesis of contractile proteins [94]. Even supplements, such as 
omega-3 and carnitine, are widely recommended in this area [96, 97].
Creatine is a molecule produced in the body, and it is a natural amine endogenously synthe-
sized by the liver, kidney, and pancreas from the amino acids arginine, glycine, and methi-
onine. It stores high-energy phosphate groups in the form of phosphocreatine that releases 
energy to aid cellular function in brain, bones, muscles, and liver. It can be found in some 
foods, mostly meat, eggs, and fish [98]. Creatine supplementation became popular in the 1990s 
for enhancing athletic performance and building lean body mass [99]. It has also been used in 
the treatment of chronic heart failure and mitochondrial disorders. Recent findings have con-
firmed the potential therapeutic effects of creatine supplementation and have demonstrated 
that in the elderly, it improves the quality of life by increasing muscle strength and resistance 
to fatigue, improving performance in daily activities, and preventing bone loss [100, 101]. As 
a supplement, it is most commonly available as a monohydrate in powder, candy, gum, and 
liquid. Many synthetic derivatives are available, including creatine malate, creatine pyruvate, 
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creatine citrate, creatine-magnesium chelate, and creatine ethyl ester. Studies with older people 
have used this regimen 2–5 g per day to ensure the saturation of muscle compound [102], and 
when it is associated with resistance training, training volume is increased, thereby enhancing 
strength and muscle mass [103].
The quality of proteins is paramount. A major stimulus in muscle anabolism has been reported 
as a result of an increase in circulating leucine levels. This was inferred from the observation 
that the ingestion of whey protein causes even more postprandial muscle protein synthesis 
rates relative to the ingestion of the intact or hydrolyzed casein and the difference is in the 
leucine content that has a key role in increasing muscle protein synthesis [104].
Whey protein can be considered a high quality protein, due to the anabolic properties attrib-
uted to the faster digestion and absorption of essential amino acids, such as leucine [105].
The mechanism of action of whey proteins is linked to the phosphorylation of p70S6K, which 
targets the ribosomal subunit S6 and thus promotes protein synthesis. It has been seen that 
its levels remain elevated even 2 hours after ingestion of whey proteins [106]. In association 
with amino acid supplementation, it is helpful to administer omega-3 fatty acid because these 
affect the membrane fluidity, endocytosis, exocytosis, absorption, and release of neurotrans-
mitters such as acetylcholine involved in muscle contraction. They also stimulate the pathway 
of protein kinase C, enhancing muscle protein synthesis [107].
A recent integrative approach is the use of melatonin. Melatonin, also known as N-acetyl-
5-methoxytryptamine, is a derivative of tryptophan, an essential amino acid [108]. It is well 
known for its role in synchronization of circadian rhythms such as sleep timing, blood pres-
sure, and seasonal reproduction [109, 110], but it is also an antioxidant molecule since it seems 
to be essential regulator of homeostasis.
Lee et al. found an inverse association between urine melatonin and sarcopenia, suggesting 
that melatonin may have a protective role in the pathophysiology of sarcopenia. Aging and 
age-related conditions show an association with low melatonin level. Considering that mela-
tonin has anti-apoptotic effects and attenuates autophagic pathways, its decrease may have a 
role in the pathogenesis of sarcopenia. Muscle is one of the systems that requires more oxygen 
and consequently generates more reactive species. Melatonin is a protective factor against this 
damage, scavenging free radicals, enhancement of antioxidant enzymes, and inhibition of 
pro-oxidant enzymes [111, 112].
Its antioxidant function is expressed by protection of the electron transport chain and mito-
chondrial DNA from oxidative damage more efficiently than other conventional antioxi-
dants. So, it increases ATP production in mitochondria [113]. For example, melatonin induces 
autophagy in myoblast cells collaborating in myogenic differentiation degradation [88], but it 
inhibits autophagy in muscles from carbon tetrachloride-treated mice by reducing oxidative 
stress-induced damage. Melatonin reduces endoplasmic reticulum stress in skeletal muscle 
by increasing the expression of several proteins as well as mRNA levels [114]; this improves 
protein synthesis. It reduces inflammation in muscle cells, acting specifically against these 
cytokines in rats [115] and also in humans [116].
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Melatonin is more than a regulator of circadian rhythm, it is an antioxidant molecule, and 
it seems to be essential as a physiological regulator of homeostasis. So, its supplementation 
may be useful to prevent or treat sarcopenia-associated diseases, including osteoporosis and 
neuromuscular dysfunction [117].
The management of weight loss in secondary sarcopenia must be evaluated with extreme 
care since it is known that any treatment of obesity is diet therapy which affects the loss of fat 
mass and lean mass. This loss of muscle mass is greater when they are prescribed diets with 
a very low calorie intake or less than 1000 kcal/day, which should be strongly discouraged in 
chronic diseases. In the management, it is necessary to ensure a moderate caloric restriction 
ensuring a gradual weight loss, from 0.5 to 1 kg per week, or a decline of 8–10% compared to 
the initial weight in 6 months. It is also necessary to ensure proper protein intake. Metabolic 
and epidemiological studies suggest that the current intake recommendations for protein in 
elderly may not be sufficient.
3.2. Reduction of chronic inflammation
Despite the different chronic conditions can lead to secondary sarcopenia, one of the factors 
underlying the development and progression is the state of chronic inflammation. The pro-
nounced anti-inflammatory effects of extremely low frequency (ELF) magnetic fields may 
improve the well-being of patients suffering from illnesses of different etiology. Human stud-
ies regarding ultralow frequency magnetic field effects have been carried out in several clini-
cal settings over the past 20 years for treating bone and joint diseases, neuropathies, spinal 
cord injury, diabetic neuropathy, immune disorders, and cardiomyopathy. Properly con-
figured signals have been demonstrated to regulate major cellular functions, including cell 
proliferation, differentiation, apoptosis, cell cycle, DNA replication, and cytokine/chemokine 
expression [118, 119].
The anti-inflammatory effects have demonstrated a decrease in pro-inflammatory cytokines 
and increase in anti-inflammatory cytokines after traumatic brain injury. Several metabolic 
parameters change in consequence of exposure to electromagnetic field, as observed in 
injured rats [120], stroke, decreased pain in osteoarthritis [121], wound  healing [122] and 
postsurgical recovery [123].
Saggini et al. show inflammatory effects of external pulsed electromagnetic fields in the 
treatment of low back pain with a decrease of pro-inflammatory cytokines (IL-6) after 40 
minutes to a sequence of electromagnetic fields of low intensity with inferior frequen-
cies at 100 KHz for a number of 10 sessions in 3 weeks [124]. Furthermore, they allow, as 
a consequence, a ionic flow capable of optimizing the intrinsic capacity of maintaining 
the intra and extracellular potential difference essential for the cellular metabolism and 
homeostasis [125].
The frequency of the field was such to “stimulate” several ions in the sense of the cyclotron 
frequency. These ions may be involved in the enzymatic chains experimentally affected. This 
issue needs to be analyzed in detail in the future through well-designed experiments [125].
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The term cyclotron frequency points to the form of resonance, which is established at the 
level of cell membranes, using electromagnetic fields at a very low intensity and at a specific 
frequency (cyclotron), able to influence and stimulate the metabolism of human cells. It acts 
to adjust the ordered traffic of selected ions between the internal and external environments 
of the cell; it stimulates the activity of those ion-dependent enzymes allowing the occurrence 
of several biological reactions [126].
The bioresonance cyclotron technology (Figure 5) (Quantum Electrodynamic Catalysis) is 
able to provide magnetic fields that respond to the laws of quantum electrodynamics consis-
tency (QUEC), i.e. fields that interact with the “Domains of Consistency” of water, contained 
in every living being, animal, and plant. The advantage of quanto-elettrodinamica (QUEC) 
technology is to be able to influence the movement of different ion species to the cell mem-
branes and stimulate the formation of coherent structures by strengthening the metabolism 
and cell cooperation (homeostasis) [125, 126].
Exposure to bio-cyclotron resonance technology determines: a change of configuration of the 
water; the normalization of the ion concentration in intracellular and extracellular fluid; the 
biocatalytic stimulation of intracellular enzymatic functions [127, 128].
With ion cyclotron resonance, we have the possibility to intervene in noninvasive, natural and 
precise way, on body’s homeostasis adjustment mechanisms, where the only pharmacologi-
cal support can be incomplete.
Figure 5. Ion cyclotron resonance with QUEC PHISIS QPS1.
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Therefore, it is possible to:
1. Rebalance subjective metabolism
2. Adjust the enzyme functions, the ion channels, and the body pH3.
3. Strengthen the immune system
4. Encourage the bioavailability and absorption of nutrients for cell metabolism
5. Treat neuralgia, headaches, and migraines
6. Stimulate healing in all kinds of wounds, even after surgery
7. Balance the water retention
8. Enhance the effect of drugs and supplements
9. Detoxify and to allow antioxidant function against free radicals, metabolites, and toxins 10.
10. Stimulate a painkiller function (acute and chronic)
11. Get muscle relaxation, from anxiety and stress
12. Improve the homeostasis recovery under stress (physiological microtrauma and muscle 
protein catabolism).
3.3. Physical exercise
In patients with secondary sarcopenia, both aerobic exercise (endurance) and the anaerobic 
exercise (resistance) are able to reduce sarcopenia and increase muscular strength and muscle 
power. Habitual physical inactivity of these patients is due to a number of barriers: socio-
economic, psychological, and clinics.
From a clinical point of view, these patients are fragile and sedentary with significant comorbid con-
ditions, such as osteoporosis, anemia, and heart failure, which often limit their access to physical exer-
cise. Theoretically, a physical exercise could be harmful as it may increase temporarily the risk of fatal 
and nonfatal cardiovascular events, especially if in the presence of other cardiovascular risk factors.
The recommends pre-participation of exercise protocols, provide cardiovascular evaluation by 
means of history (personal and family history) and physical examination alone, although this 
screening protocol has a recognized limited power (<10%) to detect potentially lethal cardiovas-
cular event. ECG enhances the sensitivity of the screening process by allowing early detection of 
cardiovascular conditions distinctively manifesting with ECG abnormalities. If in the course of 
screening emerge, cardiovascular abnormalities should be assessed the need for further inves-
tigation, focusing initially noninvasive, such as echocardiography, Holter monitoring, ECG-
averaging, tilt testing, the ECO-stress, myocardial scintigraphy, MRI, and cardiac CT (Table 2).
It is well known that aerobic exercise induces an increase in skeletal muscle mitochondria. In 
fact, adaptations to aerobic training appear to be the result of exercise-induced increases in 
the transcription of mitochondrial genes.
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Many studies have shown an improvement of muscle function even with aerobic or combined 
aerobic and anaerobic exercises. Aerobic training can include multiple sporting activities, 
such as stretching, walking, jogging, bicycle ergometer, and aerobic exercises. The latter often 
based on different tools: weights, elastic bands, rubber balls, rollers, and treadmill. A typical 
aerobic workout session could last about 90 minutes and be divided as follows: 15–20 minutes 
of stretching exercises, 20–50 minutes pedaling bicycle ergometer, and 20 minutes of recovery 
phase [129]. It should start with a lower intensity of training, with the shortest duration and 
for a few days a week [130]. Several authors showed a significant improvement in aerobic 
exercise capacity and muscle strength; an improvement in insulin resistance and anorexia; 
and an increase in ejection fraction, cardiac output, and stroke volume after 6 months of 
training. Aerobic exercise is related to significant reduction of systolic and diastolic pressure 
values [108] and an improvement in strength and muscle power [131]. It is well established 
that traditional, slow-velocity resistance exercise (RE) performing the concentric and eccen-
tric phase of each muscle contraction in 2–3 s is a safe, feasible, and effective intervention to 
induce muscle hypertrophy and increase strength. It seems to increase muscle protein syn-
thesis [132], satellite cell activation and proliferation [133], anabolic hormone production, and 
decrease in catabolic cytokine activity [134]. RE has been shown to increase both type I and II 
muscle fiber cross-sectional areas and whole body leading to an increase in muscle strength. 
Resistance training needs to use a progressively increasing load to maintain the desired range 
of repetitions per set of exercise (Table 3).
Fast-velocity RE (performing the concentric phase as quickly as possible and taking 2 sec to 
perform the eccentric phase of each muscle contraction) appears to be a novel intervention 
for older adults to enhance muscle power. With the subsequent atrophy of type II fibers with 
aging, fast-velocity movements are important for preserving aging muscle health. Several 
studies have shown a significant increase in muscle power with fast velocity RE in older 
adults, because of greater motor unit recruitment of type II fibers [135].
Physical training can improve balance and stability and thus has been recommended as part 
of rehabilitative exercise protocols. Studies demonstrate significant flexibility improvements 
(some joints show range of motion improvements of greater than 40%) with supervised exer-
cise programs, including static stretching or a combination of stretching and movements 
Absolute Relative
Unstable coronary heart disease Major risk factors for coronary heart disease
Decompensated heart failure Decompensated diabetes
Severe pulmonary arterial hypertension (mean arterial 
pressure >55 mmHg)
Hypertension above 160/100 mmHg
Uncontrolled arrhythmias Patients with pacemakers or defibrillators
Uncontrolled high blood pressure (>180/110 mmHg)
Marfan’s syndrome
Severe symptomatic aortic stenosis, aortic dissection
Table 2. Contraindications to exercise training.
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through a full range of motion [136]. The recovery of proprioception is an essential part of 
the recovery of sarcopenia for the recovery the motor task is to be made through advanced 
systems for muscle strength and balance. I-Moove (Figure 6) has a balancing platform with 
helispheric movement and continuous realignment of spatial plans and subsystems of the 
body in order to maintain an optimal posture in open chain or to exert a tensile force. It also 
provides a real-time visual feedback that allows to monitor corrections [137].
It is possible to use whole body vibration and focal vibration system that is an effective 
method to activate the proprioceptive sensory system. It consists of the excitation of the affer-
ents coming from the neuromuscular spindle. This causes the activation of a large number 
Type of training Frequency Intensity Duration/set
Aerobic exercise A minimum of 5 days/week 
for moderate intensity or 
3 days/week for vigorous 
intensity
Moderate intensity
40–60% VO
2
 max
40–60% VO
2
 max
40–60% VO
2
 max
3–6 METS
Accumulate at least 30 min/
day of moderate-intensity 
activity, in bouts of at least 
10 min each; continuous 
vigorous activity for at 
least 20 min/day
Resistance exercise 
involving the major muscle 
groups (free weights and 
machines)
At least 2 days/week Slow-to-moderate lifting 
velocity 60–80% of 1 RM
8–10 exercises
1–3 sets per exercise
8–12 repetitions (1–3 min of 
rest among set)
Power training to practice 
only after the resistance 
training
2 days/week Light-to-moderate loading 
(30–60% of 1 RM)
High repetition velocity
1–3 sets per exercise, 6–10 
repetitions
HR, heart rate; RM, repetition maximum; and METS, metabolic equivalents.
Table 3. Physical exercise indications.
Figure 6. I-Moove and rehabilitative gym at University Centre of Physical Medicine and Rehabilitation University G. d’ 
Annunzio- Chief R. Saggini.
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of alpha-motor neurons, leading to the recruitment of muscle fibers, previously inactive, to 
contribute to muscle contraction. It has been demonstrated that mechanical vibration on a 
single muscle is able to activate Ia and II afferent nerve fibers of the muscle spindle, and 
hence the alpha motor neurons: this elicits the so-called Tonic Vibration Reflex (TVR), consist-
ing in sustained contraction of the muscle vibrated and simultaneous relaxation of its prime 
antagonists. Neuromuscular electrical stimulation (NMES) is an alternative and potentially 
more effective mean than exercise alone of increasing the force of muscles. These alterna-
tive approaches to exercise offered a safe addition to a traditional, high-intensity volitional 
strengthening program with the aim to implement muscular mass and strength (as described 
in chapter Rehabilitation in sarcopenic elderly)
4. Dynamic antigravity postural system (SPAD)
SPAD®, a device for body weight relief, consisting of a machinery designed to reduce, 
modify, and condition the force of gravity acting on the body structures of movement dur-
ing the act of rectilinear motion (Figure 7). The system is based on the rational that gait 
training can be made combining the motor task to sensory feedback, in line with the mul-
tisensory approach to postural balance. The system consists of a treadmill on which the 
patient carries out training in body weight support and of a structure to which the patient 
is harnessed by means of a pneumatic belt placed between the iliac crests and the costal 
arches, connected to lifting system with four tie rods attached to the body and to the pel-
vic girdle. Equipment is completed by four front pads (two on the humeral heads for the 
shoulder girdle and two on the anterior superior iliac spine for the pelvis), which act as 
stabilizers (as they prevent possible twisting of the pelvis or shoulder during movement 
on the treadmill), and at the same time as informants proprioceptive. Two rear pads can be 
placed on the interscapular region and on the sacral area; according to the characteristics of 
Figure 7. Dynamic antigravity postural system (SPAD).
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the patient, an inflatable collar can also be used. Each session of SPAD® provides a 30–50% 
mean body weight relief and a training on the treadmill with adjustable speed (down to 
0.01 km/h during the first session, allowing to become familiar with the machine and thus 
obtaining a higher compliance). The harnessing in body weight support allows the vertical 
excursion of the center of gravity of the subject, facilitating the execution of longer steps, 
according to the possibilities of the individual patient; the step performing is corrected 
continuously by the operator, inviting the patient to get an ordered cadence with sequen-
tial placement of heel-plant-toe. In this way, session after session, SPAD® allows to change 
asymmetrical gait adaptations, working with a dual action: a mechanical one, which allows 
a neuromotor retraining with cortical-subcortical learning aimed to the reacquisition of a 
balanced body schema that minimizes the energy consumption needed to maintain the pos-
ture, and a proprioceptive one, which acts on the maintenance of automatic and induced 
over time walking adaptations. The last part of the session provides for the reduction of 
body weight relief gradually to 0% and the reduction of the speed of the treadmill until 
the stop; in this way, in the last part of the session, the patient continuing to maintain the 
proprioceptive stimulus [138–140].
5. Exercises in virtual reality
Virtual reality exercises in the proposed protocol are based on the most recent findings about 
the neurophysiology of learning processes and movement memorization. The virtual reality 
system Riablo® is based on the use of sensors connected to a screen, which in real time sent 
the exact awareness of the carried out motor task to the patient, with the possibility to focus 
attention only on the fundamental elements of the movement reducing distracting stimuli 
from the surrounding real environment. It is possible to set a series of exercises: stand up 
from the chair; displacement of the load with bending knees; displacement of the load on the 
sagittal plane; displacement of the load on the sagittal and frontal planes; and bilateral squats 
with back support. The resulting motor performances and the collected kinematic data are 
entirely analyzed and recorded in the system, which calculate a score. This motivational input 
rewards the patient’s efforts, ensuring faster progress [141].
6. Microgravity aquatic therapy
Aquatic therapy is based upon several important bioengineering properties. The basic forces 
acting upon the patient while in the water consist of buoyancy, drag, and inertial forces. 
Additional factors affecting the patient include hydrostatic pressure and specific heat. Various 
properties of water contribute to therapeutic effects, including the ability to use water for 
resistance in place of gravity or weights. Thermal stability that permits maintenance of near-
constant temperature; hydrostatic pressure that supports, stabilizes and influences heart 
and lung function; buoyancy that permits floatation and reduces the effects of gravity; and 
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 turbulence and wave propagation that allow gentle manipulation and movement. In our clini-
cal experience, microgravity aquatic therapy can restore active range of motion. In the water, 
where resistance of water changes depending on walking speed, it is possible to adjust the 
exercise intensity. Compared to slow movements, such as walking, the body is subjected to 
greater levels of water resistance with movements that require use of great muscle strength 
in a short period of time. Previous studies have found that by exercising in the water, where 
buoyancy makes it difficult to support the body, people can experience postural instabil-
ity and improve dynamic balance and muscle strength [142]. As far as exercise safety was 
concerned, in the water buoyancy and viscosity, lower forces applied to body mass-bearing 
joints, such as the knee, and as a result, the aquatic exercise did not damage muscles and 
joints. Moreover, in the present aquatic exercise training, the level of intensity can be defined 
as “moderately strong.”
7. Resistance exercise with Kineo system
Changes related to sarcopenia have negative implications on metabolism, cardiovascular, and 
muscular function. Physical exercise is the most effective intervention to improve quality of 
life, physical, and psychological health [143].
Physical exercise acts on all the physiopathological mechanisms of sarcopenia: increases 
mTOR expression that controls protein synthesis in the muscle in response to exercise and 
nutrition; decreases fat infiltration and prevents lipotoxicity; and regulates oxidative stress 
through activation of mitochondrial genes and optimization of energy production, increase of 
capillary density, and muscle perfusion.
A training program that includes endurance and resistance exercises has more positive effects 
on sarcopenic muscle: resistance exercises are more effective in increasing muscle mass and 
strength, whereas endurance exercises are more effective for improving maximum aerobic 
power [144].
Increase of muscle strength and mass can be achieved with an innovative system, such as the 
KINEO system: a multitasking ergonomic robotic platform that will give you the opportunity 
to differentiate the activities of muscular work in a highly efficient and accurate way. It is the 
only robotic platform that allows to differentiate the workload in the two movement phases: 
concentric and eccentric. This allows to optimize the training of strength and also to work 
with maximum loads in the concentric phase, as it reduces the load in the return movement.
Kineo (Figure 8) is the only robotic platform that allows to differentiate the workload in 
the two movement phases: concentric and eccentric. This allows to optimize the training of 
strength and also to work with maximum loads in the concentric phase, as it reduces the load 
in the return movement.
The Kineo system makes it possible to perform the movement with or without inertia: 
in the latter case, the displacement of the load requires an application of muscle strength 
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throughout the movement, even in gestures characterized by great explosiveness. The set 
load remains constant in all angles and is not modified by inertia, as is the case with a tradi-
tional isotonic work. It is possible to differentiate the load between the concentric phase and 
the eccentric phase. It is possible to work in different conditions, such as elastic and “water 
viscous method.” The elastic method uses resistance bands or springs as external resistance. 
The elongation of an elastic element depends on the strength applied to it by the subject and 
the nature of the elastic material (elastic constant). The advantage of the traditional elastic 
method is constituted by the gradual increase in the muscular effort while varying the work-
load is laborious.
Kineo elastic method is its ability to use differentiated loads between the concentric and 
eccentric phase to generate specific muscle adaptations and to use different methods in the 
concentric and eccentric phase.
Figure 8. Kineo system.
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Water workout is, universally, recognized as the most appropriate method for prevention 
and functional rehabilitation, because the load adapts exactly to the real strength of the 
subject. The “water viscous method,” which can be considered as the most innovative, uses 
the principle of water workout and makes it available in a classic workout station. Kineo 
offers the possibility to use six levels (Figure 9) of viscosity simulating a workout in various 
fluids, such as water, oil, honey, and so on, which correspond to different levels of muscular 
effort. One of the most important applications of the water viscous method is the work for 
the stabilization of the joints, especially the knee joint, because the progressive increase in 
the viscous load involves the individual muscle groups according to physiologically correct 
models.
The water viscous method is characterized by the following features: the load increases or 
decreases depending on the speed of movement and level of viscosity; the speed is not con-
stant but it depends on the level of applied force; and there is no inertia. When the movement 
stops, the load is immediately set to zero (maximum safety for the subject). Biphasic load: 
you can independently configure the level of viscosity in the concentric and eccentric phases 
(Figure 10). Unlike other methods, the progressive increase in the load according to the speed 
allows the subject to use a load that always respects his/her neuromuscular condition and 
prevents pain.
The training schedule with Kineo should involve two or three sessions a week in noncon-
secutive days. The workload is related to the potentialities of the individual subject, which is 
analyzed with specific tests that evaluate strength, equilibrium, speed, and power. (see http://
www.kineosystem.com/)
Figure 9. Kineo system, concentric vs. eccentric phase.
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8. Quality of life improvement
The inclusive approach to improve the quality of life includes music therapy relaxation 
training, diaphragmatic breathing, guided imagery, self-hypnosis, mindfulness meditation, 
and distracting thoughts and activities outdoor exercises being perceived as energizing and 
indoor exercises being perceived as relaxing. Using methods deriving from cognitive therapy, 
patients are taught how to identify and change unhelpful or negative thoughts (cognitive 
restructuring) that contribute to psychological distress, while facilitating coping thoughts that 
reduce distress and enhance other coping efforts. Occupational therapists can help patient to 
maintain or resume their previous social role.
9. Conclusion
Sarcopenia is a disabling condition related to various adverse health outcomes such as mental 
disorders, poor quality of life, and mortality. Acting with rehabilitation goals is important for 
promoting positive functional (strength and power) and structural (hypertrophy and phe-
notypic changes) adaptive responses. The planning of a complex rehabilitation program in 
sarcopenia associated to chronic conditions, in the context of a comprehensive treatment, is 
made up of a nutritional support, exercise, correction of lifestyles, and use of advanced physi-
cal energies. Therefore, for the purposes of the optimal management, it is essential to identify 
the pathogenesis aspects and clinical characteristics, which can affect the different treatment 
choices in rehabilitation. A specialist in the identification, evaluation, and rehabilitation of 
neuromuscular, musculoskeletal, and functional disorders associated with chronic conditions 
and its treatment emphasizing the restoration and maintenance of function and quality of life. 
Future research should focus on better understanding the role of rehabilitation and on defin-
ing appropriate interventions for sarcopenia in chronic illness.
Figure 10. Kineo system, viscous method.
Sarcopenia in Chronic Illness and Rehabilitative Approaches
http://dx.doi.org/10.5772/intechopen.70223
185
Author details
Raoul Saggini1*, Simona Maria Carmignano2, Lucia Cosenza2, Tommaso Palermo2 and Rosa 
Grazia Bellomo3
*Address all correspondence to: saggini@unich.it
1 Physical and Rehabilitation Medicine, Department of Medical Oral and Biotechnological 
Sciences, Director of the School of Specialty in Physical and Rehabilitation Medicine, 
“Gabriele d’Annunzio” University, National Coordinator of Schools of Specialty in Physical 
and Rehabilitation Medicine, Chieti-Pescara, Italy
2 School of Specialty in Physical and Rehabilitation Medicine, “Gabriele d’Annunzio” University 
of Chieti- Pescara, Italy
3 Physical and Rehabilitation Medicine, Department of Medicine and Sciences of Aging, 
“Gabriele d’Annunzio” University of Chieti-Pescara, Italy
References
[1] Morley JE, Anker SD, von Haehling S. Prevalence, incidence, and clinical impact of sarco-
penia: Facts, numbers and epidemiology—update 2014. Journal of Cachexia, Sarcopenia 
and Muscle 2014;5:253-259. DOI: 10.1007/s13539-014-0161-y
[2] Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T et al. European Working 
Group on Sarcopenia in Older People. Sarcopenia: European consensus on definition 
and diagnosis—Report of the European Working Group on Sarcopenia in Older People. 
Age and Ageing; 2010;39:412-413
[3] Kalantar-Zadeh K, Rhee C, Sim JJ, Stenvinkel P, Anker SD, Kovesdy CP. Why cachexia 
kills: Examining the causality of poor outcomes in wasting conditions. Journal of 
Cachexia, Sarcopenia and Muscle 2013;4:89-94
[4] Dovjak P. Sarcopenia in cases of cases of chronic and acute illness. Zeitschrift Fur 
Gerontologie Und Geriatrie. 2016;9:100-106. DOI: 10.1007/s00391-015-0986-9
[5] Berger MJ, Doherty TJ. Sarcopenia: Prevalence, mechanisms, and functional conse-
quences. Interdisciplinary Topics in Gerontology 2010;37:94-114
[6] Bruunsgaard H, Andersen-Ranberg K, Jeune B, Pedersen AN, Skinhøj P, Pedersen BK et 
al. A high plasma concentration of TNF-alpha is associated with dementia in centenar-
ians. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences. 
1999;54(7):M357-M364
[7] Toth MJ, Ades PA, Tischler MD, Tracy RP, LeWinter MM. Immune activation is associ-
ated with reduced skeletal muscle mass and physical function in chronic heart failure. 
International Journal of Cardiology 2006;109:179-187
[8] [8] Gratacós J, Collado A, Filella X, Sanmartí R, Cañete J, Llena J et al. Serum cyto-
kines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: A close 
Frailty and Sarcopenia - Onset, Development and Clinical Challenges186
correlation between serum IL-6 and disease activity and severity. British Journal of 
Rheumatology. 1994;33(10):927-931
[9] Rieu I, Magne H, Savary-Auzeloux I, Averous J, Bos C, Peyron MA et al. Reduction of 
low grade inflammation restores blunting of postprandial muscle anabolism and limits 
sarcopenia in old rats. Journal of Physiology. 2009;587(Pt 22):5483-5492. DOI: 10.1113/
jphysiol.2009.178319.
[10] Degens H. The role of systemic inflammation in age-related muscle weakness and wast-
ing. Scandinavian Journal of Medicine and Science in Sports 2010;20:28-38
[11] Ferrucci L, Corsi A, Lauretani F, Bandinelli S, Bartali B, Taub DD et al. The origins of 
age-related proinflammatory state. Blood. 2005;105(6):2294-2299
[12] Stenholm S, Maggio M, Lauretani F, Bandinelli S, Ceda GP, Di Iorio A et al. Anabolic and 
catabolic biomarkers as predictors of muscle strength decline: The InCHIANTI study. 
Rejuvenation Research 2010;13:3-11
[13] Ershler WB. Interleukin-6: A cytokine for gerontologists. Journal of the American 
Geriatrics Society 1993;41:176-181
[14] Sieber CC. Malnutrition in the elderly—when too much turns into too few. Zeitschrift 
für Gerontologie und Geriatrie. 2007;40(1):1-2
[15] Miller MS, Callahan DM, Toth MJ. Skeletal muscle myofilament adaptations to aging, 
disease, and disuse and their effects on whole muscle performance in older adult 
humans. Frontiers in Physiology 2014;5:369
[16] Degens H. Age-related skeletal muscle dysfunction: Causes and mechanisms. Journal of 
Musculoskeletal & Neuronal Interactions 2007;7:246-252
[17] Mathus-Vliegen EM. Obesity and the elderly. Journal of Clinical Gastroenterology 
2012;46:533-544
[18] Bouchonville MF, Villareal DT. Sarcopenic obesity: How do we treat it?. Current Opinion 
in Endocrinology, Diabetes, and Obesity 2013;20:412-419
[19] Rolland Y, Lauwers-Cances V, Cristini C, Abellan van Kan G, Janssen I, Morley JE et 
al. Difficulties with physical function associated with obesity, sarcopenia, and sarco-
penic-obesity in community-dwelling elderly women: The EPIDOS (EPIDemiologie de 
l'OSteoporose) Study. American Journal of Clinical Nutrition. 2009;89(6):1895-1900
[20] Tamene, A et al. Chronic obstructive pulmonary disease (COPD) is a common comorbid-
ity and is independently associated with adverse outcomes in African-American patients 
with heart failure. Journal of the American College of Cardiology. 2013;61(10):E728
[21] Fragoso CA, Enright PL, McAvay G, Van Ness PH, Gill TM. Frailty and respiratory 
impairment in older persons. The American Journal of Medicine 2012;125:79-86.
[22] Kon SS, Canavan JL, Nolan CM, Clark AL, Jones SE, Cullinan P et al. The 4-metre gait 
speed in COPD: Responsiveness and minimal clinically important difference. The 
European Respiratory Journal 2014;43:1298-1305
Sarcopenia in Chronic Illness and Rehabilitative Approaches
http://dx.doi.org/10.5772/intechopen.70223
187
[23] Liu CK, Leng X, Hsu FC, Kritchevsky SB, Ding J, Earnest CP, et al. The Journal of 
Nutrition, Health & Aging 2014;18:59. DOI: 10.1007/s12603-013-0369-0
[24] Jones SE, Maddocks M, Kon SSC, Canavan JL, Nolan CM, Clark AL et al. Sarcopenia in 
COPD: Prevalence, clinical correlates and response to pulmonary rehabilitation. Thorax 
2015;70:213-218
[25] Janssen I, Shepard DS, Katzmarzyk PT, Roubenoff R. The healthcare costs of sarcopenia 
in the United States. Journal of the American Geriatrics Society. 2004;52(1):80-85
[26] Debigaré R, Marquis K, Côté CH, Tremblay RR, Michaud A, LeBlanc P, et al. Catabolic/
anabolic balance and muscle wasting in patients with COPD. CHEST Journal. 
2003;124(1):83-89
[27] Gosker H, Van Mameren H, Van Dijk P, Engelen M, Van der Vusse G, Wouters E, et 
al. Skeletal muscle fibre-type shifting and metabolic profile in patients with chronic 
obstructive pulmonary disease. European Respiratory Journal. 2002;19(4):617-625
[28] Gosker H, Hesselink M, Duimel H, Ward K, Schols A. Reduced mitochondrial density 
in the vastus lateralis muscle of patients with COPD. European Respiratory Journal. 
2007;30(1):73-79
[29] Gea J, Agustí A, Roca J. Pathophysiology of muscle dysfunction in COPD. Journal of 
Applied Physiology. 2013;114(9):1222-1234
[30] Pitsiou G, Kyriazis G, Hatzizisi O, Argyropoulou P, Mavrofridis E, Patakas D. Tumor 
necrosis factor—alpha serum levels, weight loss and tissue oxygenation in chronic 
obstructive pulmonary disease. Respiratory Medicine. 2002;96(8):594-598
[31] Brunelle J, Chandel N. Oxygen deprivation induced cell death: An update. Apoptosis. 
2002;7(6):475-482
[32] Gonzalez NC, Wood JG. Alveolar Hypoxia-Induced Systemic Inflammation: What 
Low PO2 Does and Does Not Do. Advances in experimental medicine and biology. 
2010;662:27-32. doi:10.1007/978-1-4419-1241-1_3
[33] Rafferty GF, Lou Harris M, Polkey MI, Greenough A, Moxham J. Effect of hypercapnia 
on maximal voluntary ventilation and diaphragm fatigue in normal humans. American 
Journal of Respiratory and Critical Care Medicine. 1999;160(5):1567-1571
[34] England BK, Chastain JL, Mitch WE. Abnormalities in protein synthesis and degrada-
tion induced by extracellular pH in BC3H1 myocytes. American Journal of Physiology. 
Cell Physiology. 1991;260(2):C277-C282
[35] Sanders KJ, Kneppers AE, van de Bool C, Langen RC, Schols AM. Cachexia in chronic 
obstructive pulmonary disease: New insights and therapeutic perspective. Journal of 
Cachexia, Sarcopenia and Muscle. 2016;7(1):5-22
[36] Barreiro E, Peinado VI, Galdiz JB, Ferrer E, Marin-Corral J, Sánchez F, et al. Cigarette 
smoke-induced oxidative stress: A role in chronic obstructive pulmonary disease skel-
etal muscle dysfunction. American Journal of Respiratory and Critical Care Medicine. 
2010;182(4):477-488
Frailty and Sarcopenia - Onset, Development and Clinical Challenges188
[37] Ramsay D, Zochodne D, Robertson D, Nag S, Ludwin S. A syndrome of acute severe mus-
cle necrosis in intensive care unit patients. Journal of Neuropathology and Experimental 
Neurology. 1993;52(4):387-398
[38] Decramer M, De Bock V, Dom R. Functional and histologic picture of steroid-induced 
myopathy in chronic obstructive pulmonary disease. American Journal of Respiratory 
and Critical Care Medicine. 1996;153(6):1958-1964
[39] Calvani R, Miccheli A, Landi F, Bossola M, Cesari M, Leeuwenburgh C, et al. Current 
nutritional recommendations and novel dietary strategies to manage sarcopenia. The 
Journal of Frailty & Aging. 2013;2(1):38
[40] Landi F, Marzetti E, Martone AM, Bernabei R, Onder G. Exercise as a remedy for sarco-
penia. Current Opinion in Clinical Nutrition and Metabolic Care. 2014;17(1):25-31.
[41] Gea J, Orozco-Levi M, Barreiro E, Ferrer A, Broquetas J. Structural and functional 
changes in the skeletal muscles of COPD patients: The “compartments” theory. Monaldi 
Archives for Chest Disease. 2001;56(3):214-224
[42] Chopard A, Hillock S, Jasmin BJ. Molecular events and signalling pathways involved in 
skeletal muscle disuse-induced atrophy and the impact of countermeasures. Journal of 
Cellular and Molecular Medicine. 2009;13(9b):3032-3050
[43] Maltais F, LeBlanc P, Simard C, Jobin J, Bérubé C, Bruneau J, et al. Skeletal muscle adap-
tation to endurance training in patients with chronic obstructive pulmonary disease. 
American Journal of Respiratory and Critical Care Medicine. 1996;154(2):442-447
[44] O’Shea SD, Taylor NF, Paratz JD. Progressive resistance exercise improves muscle 
strength and may improve elements of performance of daily activities for people with 
COPD: A systematic review. CHEST Journal. 2009;136(5):1269-1283
[45] Seymour J, Spruit M, Hopkinson N, Natanek S, Man W-C, Jackson A, et al. The prev-
alence of quadriceps weakness in COPD and the relationship with disease severity. 
European Respiratory Journal. 2010;36(1):81-88.
[46] Pereira RA, Cordeiro AC, Avesani CM, Carrero JJ, Lindholm B, Amparo FC et al. 
Sarcopenia in chronic kidney disease on conservative therapy: Prevalence and associa-
tion with mortality. Nephrol Dial Transplant. 2015;30(10):1718-1725
[47] Zha Y, Qian Q. Protein nutrition and malnutrition in CKD. Nutrients. 2017;9:208. DOI: 
10.3390/nu9030208
[48] Du J, Wang X, Miereles C, Bailey JL, Debigare R, Zheng B, et al. Activation of caspase-3 
is an initial step triggering accelerated muscle proteolysis in catabolic conditions. J Clin 
Invest. 2004;113(1):115-123
[49] Chauveau P, Combe C, Laville M, Fouque D, Azar R, Cano N et al. Factors influenc-
ing survival in hemodialysis patients aged older than 75 years: 2.5-year outcome study. 
American Journal of Kidney Diseases. 2001;37(5):997-1003
Sarcopenia in Chronic Illness and Rehabilitative Approaches
http://dx.doi.org/10.5772/intechopen.70223
189
[50] Zhang L, Du J, Hu Z, Han G, Delafontaine P, Garcia G, Mitch WE. IL-6 and serum amy-
loid A synergy mediates angiotensin II-induced muscle wasting. Journal of the American 
Society of Nephrology. 2009;20(3):604-612
[51] Song YH, Li Y, Du J, Mitch WE, Rosenthal N, Delafontaine P. Muscle-specific expres-
sion of IGF-1 blocks angiotensin II-induced skeletal muscle wasting. Journal of Clinical 
Investigation. 2005;115(2):451-458
[52] Kuemmerle N, Krieg RJ Jr, Latta K, Challa A, Hanna JD, Chan JC. Growth hormone 
and insulin-like growth factor in non-uremic acidosis and uremic acidosis. Kidney 
International Supplements 1997;58:S102-S105
[53] Löfberg E, Essén P, McNurlan M, Wernerman J, Garlick P, Anderstam B et al. Effect of 
hemodialysis on protein synthesis. Clinical Nephrology. 2000;54(4):284-294
[54] Lim VS, Ikizler TA, Raj DS, Flanigan MJ. Does hemodialysis increase protein break-
down? Dissociation between whole-body amino acid turnover and regional muscle 
kinetics. Journal of the American Society of Nephrology. 2005;16(4):862-868
[55] Ikizler TA, Flakoll PJ, Parker RA, Hakim RM. Amino acid and albumin losses during 
hemodialysis. Kidney International. 1994;46(3):830-837
[56] Kobayashi H, Børsheim E, Anthony TG, Traber DL, Badalamenti J, Kimball SR et al. 
Reduced amino acid availability inhibits muscle protein synthesis and decreases activ-
ity of initiation factor eIF2B. American Journal of Physiology. Endocrinology and 
Metabolism. 2003;284(3):E488-E498
[57] Shyu KG, Lu MJ, Wang BW, Sun HY, Chang H. Myostatin expression in ventricular myo-
cardium in a rat model of volume-overload heart failure. European Journal of Clinical 
Investigation. 2006;36(10):713-719
[58] Cunha TF, Bacurau AV, Moreira JB, Paixão NA, Campos JC, Ferreira JC et al. Exercise 
training prevents oxidative stress and ubiquitin-proteasome system overactivity and 
reverse skeletal muscle atrophy in heart failure. PLoS One. 2012;7(8):e41701
[59] Sakuma K, Yamaguchi A. Sarcopenia and cachexia: The adaptations of negative regula-
tors of skeletal muscle mass. Journal of Cachexia, Sarcopenia and Muscle 2012;3:77-94
[60] Forbes SC, Little JP, Candow DG. Exercise and nutritional interventions for improving 
aging muscle health. Endocrine 2012;42:29-38
[61] Hambrecht R, Schulze PC, Gielen S, Linke A, Möbius-Winkler S, Yu J et al. Reduction 
of insulin-like growth factor-I expression in the skeletal muscle of noncachectic 
patients with chronic heart failure. Journal of the American College of Cardiology. 
2002;39(7):1175-1181
[62] Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classifica-
tion of cancer cachexia: An international consensus. The Lancet Oncology 2011;12:489-495
Frailty and Sarcopenia - Onset, Development and Clinical Challenges190
[63] Busquets S, Felipe A, Lopez-Soriano, FJ. Molecular mechanisms involved in muscle 
wasting in cancer and ageing: Cachexia versus sarcopenia. The International Journal of 
Biochemistry & Cell Biology 2005;37:1084-1104
[64] Argiles JM, Busquets S, Lopez-Soriano FJ. The pivotal role of cytokines in muscle 
wasting during cancer. The International Journal of Biochemistry & Cell Biology. 
2005;37:1609-1619
[65] Watanobe H, Takebe K. Intravenous administration of tumor necrosis factor-alpha stim-
ulates corticotropin releasing hormone secretion in the push-pull cannulated median 
eminence of freely moving rats. Neuropeptides. 1992;22:81-84
[66] Butler SG, Stuart A, Leng X, Wilhelm E, Rees C, Williamson J. The relationship of aspira-
tion status with tongue and handgrip strength in healthy older adults. The Journals of 
Gerontology. Series A, Biological Sciences and Medical Sciences. 2011;66(4):452-458
[67] Wakabayashi H. Presbyphagia and sarcopenic dysphagia: Association between aging, 
sarcopenia, and deglutition disorders. The Journal of Frailty & Aging. 2014;3(2):97-103
[68] Guidoz Y, Wellas BJ, Garry PJ. Mini Nutritional Assessment: A practical assessment 
tool for grading the nutritional state of elderly patient. In: Wellas BJ, Guidoz Y, Garry 
PJ, Albarede JL, eds. Nutrition in the Elderly, the Mini Nutritional Assessment (MNA). 
Facts and Research in Gerontology 1994/1995. 2nd ed. Paris: Serdi Publishing Company; 
1995. pp. 15-60
[69] Kaiser MJ, Bauer JM, Ramsch C et al. The Journal of Nutrition, Health & Aging 
2009;13:782. DOI: 10.1007/s12603-009-0214-7
[70] Kaur S, Miller MD, Halbert J, Giles LC, Crotty M. Nutritional status of adults par-
ticipating in ambulatory rehabilitation. Asia Pacific Journal of Clinical Nutrition. 
2008;17(2):199-207
[71] Strupp BJ, Levitsky DA. Enduring cognitive effects of early malnutrition: A theoretical 
appraisal. Journal of Nutrition 1995;125:2221S-2232S.
[72] Jentoft AJ, Baeyens JP, Bauer JM et al. Sarcopenia: European consensus on definition and 
diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age 
and Ageing. 2010;39(4):412-423
[73] Mitsiopoulos N, Baumgartner RN, Heymsfield SB, Lyons W, Gallagher D et al. Cadaver 
validation of skeletal muscle measurement by magnetic resonance imaging and comput-
erized tomography. Journal of Applied Physiology. 1998;85(1):115-122
[74] Levine JA, Abboud L, Barry M, Reed JE, Sheedy PF, Jensen MD. Measuring leg muscle 
and fat mass in humans: Comparison of CT and dual-energy X-ray absorptiometry. 
Journal of Applied Physiology. 2000;88(2):452-456
[75] Vona-Davis, Rose DP. Adipokines as endocrine, paracrine, and autocrine factors in 
breast cancer risk and progression. Endocrine-Related Cancer. 2007;14(2):189-206
Sarcopenia in Chronic Illness and Rehabilitative Approaches
http://dx.doi.org/10.5772/intechopen.70223
191
[76] Sullivan DH, Walls RC, Bopp MM. Protein energy undernutrition and the risk of mortal-
ity within one years of hospital discharge: A follow-up study. Journal of the American 
Geriatrics Society 1995b;43:507-512
[77] Fanelli MT, Kuczmarski RJ. Ultrasound as an approach to assessing body composition. 
American Journal of Clinical Nutrition1984;39(5):703-709
[78] Kuczmarski RJ, Fanelli MT, Koch GG. Ultrasonic assessment of body composition in 
obese adults: Overcoming the limitations of the skinfold caliper. American Journal of 
Clinical Nutrition. 1987;45(4):717-724
[79] Leahy S, Toomey C, McCreesh K, O’Neill C, Jakeman P. Ultrasound measurement of 
subcutaneous adipose tissue thickness accurately predicts total and segmental body fat 
of young adults. Ultrasound in Medicine and Biology. 2012;38(1):28-34
[80] Volz PA, Ostrove SM. Evaluation of a portable ultrasonoscope in assessing the 
body composition of college-age women. Medicine & Science in Sports & Exercise. 
1984;16(1):97-102
[81] Abe T, Kondo M, Kawakami Y, Fukunaga T. Prediction equations for body composi-
tion of Japanese adults by B-mode ultrasound. American Journal of Human Biology. 
1994;6(2):161-170.
[82] Saito K, Nakaji S, Umeda T, Shimoyama T, Sugawara K, Yamamoto Y. Development 
of predictive equations for body density of sumo wrestlers using B-mode ultrasound 
for the determination of subcutaneous fat thickness. British Journal of Sports Medicine. 
2003;37(2):144-148.
[83] Eston R, Evans R, Fu F. Estimation of body composition in Chinese and British men 
by ultrasonographic assessment of segmental adipose tissue volume. British Journal of 
Sports Medicine. 1994;28(1):9-13.
[84] Silva L. An Introduction to Ultrasound and the BodyMetrixSystem. Livermore, 
California, USA: IntelaMetrix; 2010.
[85] Watanabe Y, Yamada Y, Fukumoto Y, Ishihara T, Yokoyama K, Yoshida T et al. Echo 
intensity obtained from ultrasonography images reflecting muscle strength in elderly 
men. Clinical Interventions in Aging 2013;8:993-998
[86] Lauretani F, Russo CR, Bandinelli S, Bartali B, Cavazzini C, Di Iorio A,. Age-associated 
changes in skeletal muscles and their effect on mobility: An operational diagnosis of 
sarcopenia. Journal of Applied Physiology. 2003;95(5):1851-1860
[87] Roberts HC, Denison HJ, Martin HJ, Patel HP, Syddall H, Cooper C, Sayer AA. A review 
of the measurement of grip strength in clinical and epidemiological studies: Towards a 
standardised approach. Age and Ageing. 2011;40(4):423
[88] Magasi SR, Bubela DJ, Wang Y-C, Gershon RC. Grip and knee extension muscle strength 
reflect a common construct among adults. Muscle and Nerve 2012; 46:555-558.
Frailty and Sarcopenia - Onset, Development and Clinical Challenges192
[89] Bean JF, Kiely DK, Herman S, Leveille SG, Mizer K, Frontera WR, Fielding RA. The 
relationship between leg power and physical performance in mobility-limited older 
people. Journal of the American Geriatrics Society. 2002;50(3):461-467
[90] National Institute on Aging, Laboratory of Epidemiology, Demography, and Biometry. 
https://www.nia.nih.gov/
[91] Kiely DK, LaRose S, Alian J, Frontera WR. Is stair climb power a clinically relevant mea-
sure of leg power impairments in at-risk older adults? Archives of Physical Medicine 
and Rehabilitation 2007;88:604-609.
[92] Cesari M, Roger A, Pahor M, Goodpaster B, Hellerstein M, Gabor A. Biomarkers of sar-
copenia in clinical trials—recommendations from the International Working Group on 
Sarcopenia. Journal of Cachexia, Sarcopenia and Muscle 2012;3(3):181-190.
[93] Bukhari SS, Phillips BE, Wilkinson DJ, Limb MC, Rankin D, Mitchell WK, et al. Intake of 
low-dose leucine-rich essential amino acids stimulates muscle anabolism equivalently 
to bolus whey protein in older women at rest and after exercise. American Journal of 
Physiology. Endocrinology and Metabolism. 2015;308(12):E1056-E1065.
[94] Rizzoli R. Nutrition and Sarcopenia. Journal of Clinical Densitometry. 2015;18(4):483-487.
[95] Paddon-Jones D, Rasmussen BB. Dietary protein recommendations and the pre-
vention of sarcopenia. Current Opinion in Clinical Nutrition and Metabolic Care. 
2009;12(1):86-90
[96] Saggini R, Calvani M. The treatment of cancer: a comprehensive therapeutic model 
entailing a complex of interaction modalities. DOI: 10.5772/55696
[97] Saggini R, Bellomo RG, Carmignano SM, Saggini A. Cancer pain—The role of an inte-
grated, comprehensive rehabilitation program in its management. In: Rangel LBA, 
Silva IA, editors. Updates on Cancer Treatment. Rijeka, Croatia, InTech; 2015
[98] Wyss M, Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiological 
Reviews 2000;80:1107-1213.
[99] Candow DG. Sarcopenia: Current theories and the potential beneficial effect of creatine 
application strategies. Biogerontology. 2011;12:273-281.
[100] Gualano B, Artioli GG, Poortmans JR, Lancha Junior AH. Exploring the therapeutic role 
of creatine supplementation. Amino Acids 2010;38:31-44.
[101] Rawson ES, Wehnert ML, Clarkson PM. Effects of 30 days of creatine ingestion in 
older men. European Journal of Applied Physiology and Occupational Physiology 
1999;80:139-144.
[102] Hultman E, Söderlund K, Timmons JA, Cederblad G, Greenhaff PL. Muscle creatine 
loading in men. Journal of Applied Physiology 1996;81:232-237.
[103] Gualano B, Roschel H, Lancha-Jr AH, Brightbill CE, Rawson ES. In sickness and in 
health: The widespread application of creatine supplementation. Amino Acids 
2012;43:519-529.
Sarcopenia in Chronic Illness and Rehabilitative Approaches
http://dx.doi.org/10.5772/intechopen.70223
193
[104] Pennings B, Boirie Y, Senden J, Gijsen AP, Kuipers H, van Loon LJ. Whey protein stimu-
lates postprandial muscle protein accretion more effectively than do casein and casein 
hydrolysate in older men. The American Journal of Clinical Nutrition 2011;93:997-1005.
[105] Burd NA, Yang Y, Moore DR, Tang JE, Tarnopolsky MA, Phillips SM. Greater stimula-
tion of myofibrillar protein synthesis with ingestion of whey protein isolate v. micellar 
casein at rest and after resistance exercise in elderly men. British Journal of Nutrition. 
2012;108:958-962.
[106] Mitchell CJ, Della Gatta PA, Petersen AC, Cameron-Smith D. Soy protein ingestion 
results in less prolonged p70S6 kinase phosphorylation compared to whey protein after 
resistance exercise in older men. Journal of the International Society of Sports Nutrition 
2015; 12:6. DOI: 10.1186/s12970-015-0070-2.
[107] Di Girolamo FG, Situlin R, Mazzucco S. Omega-3 fatty acids and protein metabolism: 
Enhancement of anabolic interventions for sarcopenia. Nutrition in Clinical Practice. 
2013;28(6):684-690. DOI: 10.1177/0884533613507607.
[108] Stehle J, Reuss S, Riemann R, Seidel A, Vollrath L. The role of arginine-vasopressin 
for pineal melatonin synthesis in the rat: Involvement of vasopressinergic receptors. 
Neuroscience Letters 1991;123:131-134.
[109] Dawson D, Encel N. Melatonin and sleep in humans. Journal of Pineal Research 
1993;15:1-12.
[110] Pechanova O, Paulis L, Simko F. Peripheral and central effects of melatonin on blood 
pressure regulation. International Journal of Molecular Sciences 2014, 15, 17920-17937.
[111] Erkanl N K, Kayalar N, Ercan F, Sener G, KNrali K. Melatonin protects against isch-
emia/reperfusion injury in skeletal muscle. Journal of Pineal Research. 2005;39:238-242
[112] Lee JY, Kim JH, Lee DC. Urine melatonin levels are inversely associated with sar-
copenia in postmenopausal women. Menopause. 2014; 21(1):39-44. DOI: 10.1097/
GME.0b013e318291f6c8.
[113] Ramis MR, Esteban S, Miralles A, Tan DX, Reiter R. Protective effects of melatonin 
and mitochondria-targeted antioxidants against oxidative stress: A review. Current 
Medicinal Chemistry 2015;22:2690-2711
[114] Kim CH, Kim KH, Yoo YM. Melatonin-induced autophagy is associated with degrada-
tion of MyoD protein in C2C12 myoblast cells. Journal of Pineal Research 2012;53:289-297
[115] Borges LS, Dermargos A, da Silva J EP, Weimann E, Lambertucci RH, Hatanaka E. 
Melatonin decreases muscular oxidative stress and inflammation induced by strenu-
ous exercise and stimulates growth factor synthesis. Journal of Pineal Research. 
2015;58:166-172.
[116] Ochoa JJ, Díaz-Castro J, Kajarabille N, García C, Guisado IM, de Teresa C, Guisado 
R. Melatonin supplementation ameliorates oxidative stress and inflammatory signal-
ing induced by strenuous exercise in adult human males. Journal of Pineal Research 
2011;51:373-380.
Frailty and Sarcopenia - Onset, Development and Clinical Challenges194
[117] Coto-Montes A, Boga JA, Reite RJ. Melatonin as a potential agent in the treatment of 
sarcopenia. International Journal of Molecular Sciences 2016;17(10):177. DOI: 10.3390/
ijms17101771
[118] Aaron RK, Ciombor DM, Simon BJ. Treatment of nonunions with electric and electro-
magnetic fields. Clinical Orthopaedics 2004;419:21-29.
[119] Pesce M, Patruno A, Speranza L, and Reale M. Extremely low frequency electromagnetic 
field and wound healing: Implication of cytokines as biological mediators. European 
Cytokine Network 2013;24:1-10
[120] Rasouli J, Lekhraj R, White NM, Flamm ES, Pilla AA, Strauch B, Casper D. Attenuation 
of interleukin-1beta by pulsed electromagnetic fields after traumatic brain injury. 
Neuroscience Letters 2012;519:4-8.
[121] Nelson FR, Zvirbulis R, and Pilla AA. Non-invasive electromagnetic field therapy pro-
duces rapid and substantial pain reduction in early knee osteoarthritis: A randomized 
double-blind pilot study. Rheumatology International 2013;33:2169-2173.
[122] Pesce M, Patruno A, Speranza L, and Reale M. Extremely low frequency electromagnetic 
field and wound healing: Implication of cytokines as biological mediators. European 
Cytokine Network 2013;24:1-10.
[123] Heden, P and Pilla AA. Effects of pulsed electromagnetic fields on postoperative pain: 
A double-blind randomized pilot study in breast augmentation patients. Aesthetic 
Plastic Surgery 2008; 32, 660-666
[124] Saggini R, Bellomo RG, Saggini A, Iodice P, Toniato E. Rehabilitative treatment for 
low back pain with external pulsed electromagnetic fields. International Journal of 
Immunopathology and Pharmacology. 2009;22(3 suppl):25-28
[125] Saggini R, Scarcello L, Carmignano SM, Khodor H, Visciano C, Giuliani L. Complex 
Rehabilitation Project in Leigh syndrome. Journal of Clinical Trials. 2014;4:196
[126] Lappin MS, Lawrie FW, Richards TL, Kramer ED. Effects of a pulsed electromagnetic 
therapy on multiple sclerosis fatigue and quality of life: A double-blind, placebo con-
trolled trial. Alternative Therapies in Health and Medicine. 2003;9(4):38-48
[127] Di Bonaventura G, Saggini R, Giuliani L, Bellomo RG et al. Exposure to extremely low 
frequencies electromagnetic field aspects biofilm formation by cystic fibrosis patho-
gens. Future Microbiology 2014;10.
[128] Gerardi G, De Ninno A, Prosdocimi M, Ferrari V, Barbaro F, et al. Effects of electro-
magnetic fields of low frequency and low intensity on rat metabolism. BioMagnetic 
Research and Technology 2008;6:3.
[129] Hernandez A, Cheng A, Westerblad H. Antioxidants and skeletal muscle performance: 
“common knowledge” vs. experimental evidence. Frontiers in Physiology. 2012;3:46. 
DOI: 10.3389/fphys.2012.00046
[130] Hurley BF, Hanson ED, Sheaff AK. Strength training as a countermeasure to aging 
muscle and chronic disease. Sports Medicine 2011;41:289.
Sarcopenia in Chronic Illness and Rehabilitative Approaches
http://dx.doi.org/10.5772/intechopen.70223
195
[131] Binder E, Schechtman K, Ehsani A, Steger-May KMA, Brown M, Sinacore DR, et 
al. Effects of exercise training on frailty in community-dwelling elderly adults: 
Results of a randomized, controlled trial. Journal of the American Geriatrics Society. 
2002;50(12):1921-1928
[132] Schulte JN, Yarasheski KE. Effects of resistance training on the rate of muscle protein 
synthesis in frail elderly people. International Journal of Sport Nutrition and Exercise 
Metabolism 2001;11:S111-S118.
[133] Candow DG, Chilibeck PD, Abeysekara S, Zello GA J. Short-term heavy resistance 
training eliminates age-related deficits in muscle mass and strength in healthy older 
males. Journal of Strength and Conditioning Research. 2011;25(2):326-333.
[134] Liu CJ, Latham NK. Progressive resistance strength training for improving physical 
function in older adults. Cochrane Database of Systematic Reviews. 2009;8(3):CD002759.
[135] Reid KF, Callahan DM, Carabello RJ, Phillips EM, Frontera WR, Fielding RA. Lower 
extremity power training in elderly subjects with mobility limitations: A randomized 
controlled trial. Aging Clinical and Experimental Research. 2008;20(4):337-343.
[136] American Geriatrics Society, British Geriatrics Society, and American Academy of 
Orthopaedic Surgeons Panel on Falls Prevention. Guideline for the prevention of falls 
in older persons. Journal of the American Geriatrics Society. 2001;49(5):664-672
[137] Bellomo RG, Iodice P, Maffulli N, Maghradze T, Coco V, Saggini R. Muscle strength 
and balance training in sarcopenic elderly: A pilot study with randomized controlled 
trial. European Journal of Inflammation. 2013;11:193-201
[138] Bellomo RG, Khodor H, Barassi G, Carmignano SM, Di Stefano A, Di Pancrazio L, 
Saggini R. Global bioprogressive rehabilitation program and postural instability in 
Parkinson’s disease. European Scientific Journal. 2014;2:310-321
[139] Saggini R, Di Pancrazio L, Pisciella V, Iodice P, Marri A, Bellomo RG. Postural anti-
gravitational reprogramming in the elderly with flexed posture. European Journal of 
Physical and Rehabilitation Medicine. 2010;46 - suppl.1 - No.2. ISSN: 1973-9087.
[140] Saggini R, Di Stefano A, Capogrosso F, Carmignano SM, D’Ettole S, Iodice P et al.Task-
oriented physical exercise using postural re-alignment with body weight support in 
chronic stroke. European Journal of Inflammation. 2013;11(3):739-749
[141] Bellomo RG, Pisciella V, Di Pancrazio L, Saggini R. The virtual images into physical reha-
bilitation. In: book abstract SIMFER the Italian Society of Physical and Rehabilitation 
Medicine 37th National Congress. Campobasso, Italy; 20-23 September 2009; 189.
[142] Devereux K, Robertson D, Briffa NK. Effects of a water-based training on women 65 
years and over: A randomised controlled trial. The Australian Journal of Physiotherapy 
2005;51:102-108
[143] Montero-Fernández N, Serra-Rexach JA. Role of exercise on sarcopenia in the elderly. 
European Journal of Physical and Rehabilitation Medicine. 2013;49(1):131-143
[144] Phu S, Boersma D, Duque G. Exercise and sarcopenia. Journal of Clinical Densitometry. 
2015;18(4):488-492
Frailty and Sarcopenia - Onset, Development and Clinical Challenges196
